Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Longevity Acquisition Corp (LOAC)

Longevity Acquisition Corp (LOAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
4D pharma Announces Completion of Merger With Longevity Acquisition Corporation Business Wire - Mon Mar 22, 2021

4D pharma plc (Nasdaq: LBPS; AIM: DDDD) ("4D pharma" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the...

DDDD.LN : 16.660 (unch)
LOAC : 13.45 (+1.89%)
4D Pharma Announces Private Placement Business Wire - Wed Mar 17, 2021

4D pharma plc (AIM: DDDD) ("4D" or the "Company"), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces...

DDDD.LN : 16.660 (unch)
LOAC : 13.45 (+1.89%)
4D Pharma to Present at Upcoming Investor Conferences in March Business Wire - Wed Mar 3, 2021

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announced that 4D management...

DDDD.LN : 16.660 (unch)
LOAC : 13.45 (+1.89%)
4D Pharma Appoints John Beck as Chief Financial Officer and Member of the Management Team Business Wire - Mon Mar 1, 2021

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of...

DDDD.LN : 16.660 (unch)
LOAC : 13.45 (+1.89%)
4D Pharma Announces U.S. SEC Declares Registration Statement Effective with Respect to the Issuance of 4D Pharma American Depositary Shares on NASDAQ Business Wire - Fri Feb 26, 2021

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces that the United...

DDDD.LN : 16.660 (unch)
LOAC : 13.45 (+1.89%)
4D pharma Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with BAVENCIO® for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma Business Wire - Mon Feb 8, 2021

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced a clinical trial...

DDDD.LN : 16.660 (unch)
LOAC : 13.45 (+1.89%)
4D Pharma Presents Update on Oncology Program Business Wire - Wed Feb 3, 2021

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces progress on activities...

DDDD.LN : 16.660 (unch)
LOAC : 13.45 (+1.89%)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of SNSS, LOAC, FBSS, and CPAH Mergers Globe NewsWire - Thu Jan 7, 2021

WILMINGTON, Del., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating:

SNSS : 18.62 (+24.30%)
LOAC : 13.45 (+1.89%)
FBSS : 21.28 (+0.47%)
CPAH : 3.48 (+0.43%)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of ELY, LOAC, ROCH, and NGA Mergers Globe NewsWire - Thu Dec 17, 2020

WILMINGTON, Del., Dec. 17, 2020 (GLOBE NEWSWIRE) --

ELY : 21.33 (-2.82%)
LOAC : 13.45 (+1.89%)
ROCH : 28.90 (+12.23%)
NGA : 16.17 (-6.53%)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Longevity Acquisition Corporation Merger Globe NewsWire - Wed Dec 2, 2020

WILMINGTON, Del., Dec. 02, 2020 (GLOBE NEWSWIRE) --

LOAC : 13.45 (+1.89%)

Barchart Exclusives

Thanks to Wall Street, Novo Nordisk Stock is Now a Buy Barchart - Sat Nov 2, 10:15AM CDT
Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a valuation a third cheaper than competitor, Eli Lilly. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot